Latest News

Beyond remission: redefining the goal of schizophrenia management

 

REVIEWER: Marc-André Roy, MD, Associate Professor of Psychiatry and Neurosciences, Université Laval, Québec City, Canada


Remission vs. functional recovery
Continuum of treatment goals

An important goal of schizophrenia management is to reduce the frequency, severity and duration of psychotic episodes (Hasan et al. World J Biol Psychiatry 2012;13: 318-378; Lehman et al. APA, NGC-3572, 2008). Indeed, it has been shown that about 70-80% of first-episode patients do achieve a remission of psychotic symptoms within the first year of treatment (Lieberman et al. Arch Gen Psychiatry 1993;50:369-376). Among patients receiving maintenance antipsychotic therapy, a systematic review estimated that the one-year recurrence rate was only 3%, compared to a 90% risk of relapse at two years in those who discontinued medication (Zipursky et al. Schizophr Res 2014;152:408-414).    Read More

Natalizumab in progressive MS: Phase II results

 

A number of preliminary studies have investigated the possible effects of natalizumab in progressive MS. The latest is the open-label phase IIb NAPMS trial that examined the effect of treatment on osteopontin, an inflammatory marker, and CSF neurofilament (NfL) light chain, a marker of axonal damage  (Romme Christensen et al. Neurology 2014;82:1499-1507). Read More

TOPICS:

Citalopram a mixed blessing for AD agitation

 

The Citalopram for Agitation in Alzheimer Disease Study (CitAD) randomized 186 AD patients with clinically significant agitation to psychosocial intervention with or without citalopram 30 mg/day for nine weeks (Porsteinsson et al. JAMA 2014;311:682-691). The dose of citalopram was titrated from 10 mg/day to the planned dose of 30 mg/day over three weeks. Read More

TOPICS:

ACTH revisited: melanocortins and MS

 

 

Melanocortin system
Immune effects of ACTH-MCR interactions
ACTH vs. steroids
Commentary by Dr. Daniel Selchen, University of Toronto, Canada
NeuroSens Survey

A few decades ago, adrenocorticotropic hormone (ACTH) was routinely used for managing acute relapses in patients with multiple sclerosis. The efficacy of this approach was demonstrated in what was perhaps the first multicentre placebo-controlled study in MS, which also introduced the Disability Status Scale (DSS) as an endpoint (Rose et al. Trans Am Neurol Assoc 1969;94:126-133). Read More

TOPICS: